Next Science Limited (NXS.AX)
AUD 0.1
(-1.0%)
AUD 0.1
(-1.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.42 Million USD | -32.02% |
| 2022 | -17.01 Million USD | -44.88% |
| 2021 | -11.74 Million AUD | 31.64% |
| 2020 | -17.18 Million AUD | 0.23% |
| 2019 | -17.22 Million AUD | 5.63% |
| 2018 | -18.25 Million AUD | -39334.44% |
| 2017 | -46.28 Thousand AUD | 98.9% |
| 2016 | -3.27 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -7.89 Million AUD | 24.68% |
| 2023 FY | - USD | -32.02% |
| 2023 Q2 | -11.45 Million AUD | -38.67% |
| 2023 Q4 | -10.99 Million AUD | 4.0% |
| 2022 Q2 | -8.71 Million AUD | -27.32% |
| 2022 FY | - USD | -44.88% |
| 2022 Q4 | -8.26 Million AUD | 5.23% |
| 2021 FY | - AUD | 31.64% |
| 2021 Q2 | -5.17 Million AUD | 28.86% |
| 2021 Q4 | -6.84 Million AUD | -32.32% |
| 2020 FY | - AUD | 0.23% |
| 2020 Q2 | -10.01 Million AUD | -20.11% |
| 2020 Q4 | -7.27 Million AUD | 27.36% |
| 2019 Q4 | -8.33 Million AUD | 6.03% |
| 2019 FY | - AUD | 5.63% |
| 2019 Q2 | -8.87 Million AUD | -112.73% |
| 2018 FY | - AUD | -39334.44% |
| 2018 Q4 | -4.16 Million AUD | 0.0% |
| 2017 FY | - AUD | 98.9% |
| 2016 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Althea Group Holdings Limited | -28.56 Million AUD | 49.505% |
| Cann Group Limited | -35.53 Million AUD | 59.416% |
| ECS Botanics Holdings Ltd | 3.22 Million AUD | 546.734% |
| Ecofibre Limited | -38.34 Million AUD | 62.388% |
| Elixinol Wellness Limited | -6.8 Million AUD | -111.899% |
| Hygrovest Limited | -1.1 Million AUD | -1207.514% |
| IDT Australia Limited | -5.13 Million AUD | -180.964% |
| Invion Limited | -4.57 Million AUD | -215.456% |
| Little Green Pharma Ltd | -4.64 Million AUD | -210.594% |
| Live Verdure Ltd | -12.51 Million AUD | -15.269% |
| Medical Developments International Limited | -29.44 Million AUD | 51.023% |
| Vitura Health Limited | 7.07 Million AUD | 303.806% |
| Vita Life Sciences Limited | 13.09 Million AUD | 210.107% |